Cystic Fibrosis Therapeutics Market Forecast to 2024 – MarketReportsOnline

MarketReportsOnline.com adds “Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) and Pipeline Analysis – Global Forecast to 2024” report to its research store.

Pune – October 13, 2017 /MarketersMedia/ —

The market for Cystic Fibrosis Therapeutics is anticipated to grow with double digit CAGR during the forecasting period. Cystic fibrosis is among the most common life-threatening genetic disorders worldwide. It is caused by defects in a single gene known as the cystic fibrosis transmembrane conductance regulator, or CFTR.

Complete report on Global Cystic Fibrosis Therapeutics Market spread across 121 pages with providing 10 company profiles is now available at http://www.marketreportsonline.com/680598.html.

The increasing prevalence of cystic fibrosis, rising awareness about cystic fibrosis therapy, strong pipeline candidates, technological advancement and high rate of R&D initiatives are some of the major factors that are driving cystic fibrosis therapeutics market. However, high cost involved in treatment, increase in complexity of disease are restraining the cystic fibrosis therapeutics market.

Key Highlights of the Report

United States dominates the global market for cystic fibrosis therapeutics.

The EU5 countries together accounted for over 20% share of the global cystic fibrosis market in 2016.

In Asian region, the prevalence of Cystic Fibrosis is observed to be very low in countries like China, India and Japan.

On the basis of pharmacological class, the CFTR modulator captures highest share of the total CF therapeutics market in 2016.

In 2016, mucolyctics agents accounted for around xx% of the global cystic fibrosis therapeutics market.

Cystic Fibrosis patients who have reduced the levels of digestive enzymes due to improper functioning of pancreas, are treated by PERT to replace these enzymes.

In 20XX, TOBI Podhaler generated sales worth US$ 300 Million.

Italy has followed Ireland and other EU countries such as Germany, Austria, Denmark and Luxembourg in approving Orkambi for patients with CF.

Purchase a copy of this “Global Cystic Fibrosis Therapeutics Market” research report at USD 1400 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=680598.

It’s estimated that 1 in every 2,500 babies born in the UK has cystic fibrosis.

The revenues for Creon increased 22 percent in 2015, driven primarily by continued market growth.

Zenpep sales surpassed US$ 200 Million mark in 2016.

Some of the drugs that are under clinical studies are Tezacaftor (VX-661) + ivacaftor, VX-445 + tezacaftor + ivacaftor, VX-659 + tezacaftor + ivacaftor, PTI-428, AZD5634, QR-010 and POL6014 among many others.

The report titled “Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) and Pipeline Analysis – Global Forecast to 2024” provides a comprehensive assessment of the Cystic Fibrosis Therapeutics Market.

This 121 Page report with 53 Figures and 6 Tables has been studied from 8 View Points:

Global Cystic Fibrosis Therapeutics Market & Forecast (2014 – 2024)

Global Cystic Fibrosis Therapeutics Market – Major Marketed Products Sales & Forecast (2012 – 2024)

Global Cystic Fibrosis Therapeutics Market – Pharmacological Class Sales & Forecast (2015 – 2021)

By Geography – Cystic Fibrosis Therapeutics Market (2014 – 2024)

Global Cystic Fibrosis Pipeline Product Analysis – By Company & Phase of Development

Cystic Fibrosis Company Profiles, Approved & Pipeline Product Analysis

Global Cystic Fibrosis Market – Industry Trends & Developments

Global Cystic Fibrosis Market – Growth Drivers & Challenges

Cystic Fibrosis Therapeutics Market – Geographical Analysis: United States, Canada, France, Germany, Italy, Spain, United Kingdom, Australia, Japan, China, India & South Korea

Global Cystic Fibrosis Therapeutics Market – Major Marketed Products Covered: Orkambi (Lumacaftor/Ivacaftor), Kalydeco (Ivacaftor), Cayston (Inhaled Aztreonam), Pulmozyme (Dornase Alfa), TOBI/ TOBI Podhaler, Creon, Zenpep, Ventolin, Bronchitol (Inhaled Mannitol), ADEKplusTM &Ibuprofen

Global Cystic Fibrosis Therapeutics Market – Pharmacological Class: CFTR Modulators, Mucolytic Agents, Pancreatic Enzyme Replacement Products, Antibiotics

Cystic Fibrosis Company Profiles, Approved & Pipeline Product Analysis: Genentech, Inc. (A Member of the Roche Group), Novartis, Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated, AbbVie, GlaxoSmithKline, Johnson & Johnson, Allergan plc, Pharmaxis Ltd & Mylan N.V

Key Topics Covered in Global Cystic Fibrosis Therapeutics Market (http://www.marketreportsonline.com/680598-toc.html):

1. Executive Summary
2. Global Cystic Fibrosis Therapeutics Market & Forecast (2014 – 2024)
3. Global Cystic Fibrosis Therapeutics Market Share & Forecast
4. Global Cystic Fibrosis Therapeutics Market – Major Marketed Products Sales & Forecast
5. Global Cystic Fibrosis Therapeutics Market – Pharmacological Class Sales & Forecast (2015 – 2021)
6. By Geography – Cystic Fibrosis Therapeutics Market (2014 – 2024)
7. Global Cystic Fibrosis Pipeline Product Analysis – By Company & Phase of Development
8. Cystic Fibrosis Company Profiles, Approved & Pipeline Product Analysis
9. Global Cystic Fibrosis Market – Industry Trends & Developments
10. Global Cystic Fibrosis Market – Growth Drivers
11. Global Cystic Fibrosis Market – Challenges

Few Points from List of Figures Covered in Global Cystic Fibrosis Therapeutics Market:

Figure 2-1: Global – Cystic Fibrosis Therapeutics Market (Million US$), 2014 – 2016
Figure 2-2: Global – Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2017 – 2024
Figure 4-1: Global – Orkambi (Lumacaftor/Ivacaftor) Sales (Million US$), 2015 – 2016
Figure 4-2: Global – Forecast for Orkambi (Lumacaftor/Ivacaftor) Sales (Million US$), 2017 – 2021
Figure 4-3: Global – Kalydeco (Ivacaftor) Sales (Million US$), 2012 – 2016
Figure 4-4: Global – Forecast for Kalydeco (Ivacaftor) Sales (Million US$), 2017 – 2021
Figure 4-5: Global – Cayston (Inhaled Aztreonam) Sales (Million US$), 2010 – 2016
Figure 4-6: Global – Forecast for Cayston (Inhaled Aztreonam) Sales (Million US$), 2017 – 2021
Figure 4-7: Global – Pulmozyme (Dornase Alfa) Sales (Million US$), 2012 – 2016
Figure 4-8: Global – Forecast for Pulmozyme (Dornase Alfa) Sales (Million US$), 2017 – 2021
Figure 4-9: Global – TOBI/ TOBI Podhaler Sales (Million US$), 2012 – 2016
Figure 4-10: Global – Creon Sales (Million US$), 2011 – 2016
Figure 4-11: Global – Forecast for Creon Sales (Million US$), 2017 – 2021
Figure 4-12: Global – Zenpep Sales (Million US$), 2014 – 2016
Figure 4-13: Global – Forecast for Zenpep Sales (Million US$), 2017 – 2021
Figure 4-14: Global – Ventolin Sales (Million US$), 2012 – 2016
Figure 4-15: Global – Forecast for Ventolin Sales (Million US$), 2017 – 2021
Figure 4-16: Global – Bronchitol (Inhaled Mannitol) Sales (Million US$), 2013 – 2016
Figure 4-17: Global – Forecast for Bronchitol (Inhaled Mannitol) Sales (Million US$), 2017 – 2021

Browse all latest pharmaceuticals market research reports at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html.

About Us:
MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Contact Info:
Name: Hrishikesh Patwardhan
Email: Send Email
Organization: MarketReportsOnline
Phone: + 1 888 391 5441

Source URL: https://marketersmedia.com/cystic-fibrosis-therapeutics-market-forecast-to-2024-marketreportsonline/250010

For more information, please visit http://www.marketreportsonline.com/contacts/purchase.php?name=680598

Source: MarketersMedia

Release ID: 250010